8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Predicting the adult height of girls with central precocious puberty

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          There are no absolute criteria for identifying those girls with idiopathic central precocious puberty (CPP) who will benefit from gonadotropin-releasing hormone analog (GnRHa) treatment. Our objective was to predict at initial evaluation the differences between adult height (AH) and target height (TH) and (for untreated girls) the time between puberty onset and first menstruation.

          Material/Methods

          The 122 girls with CPP who reached their AH included 70 who were given GnRHa because their predicted AH was <155 cm (n=24), their luteinising hormone (LH)/follicle-stimulating hormone peaks (FSH) ratio was >0.66 (n=41) and/or their estradiol was >15 pg/ml (n=40). The other 52 were untreated because their predicted AH was >155 cm. Multiple linear regressions were performed on several subsets of variables.

          Results

          Treated: the difference between AH and TH (−0.6±5.4 cm) was predicted by (using SDS) =3.68 (height at initial evaluation – TH) − 1.94 (height at initial evaluation-predicted AH) − 4.23; R2=0.73. Untreated: the difference between AH and TH (1.7±4.3 cm) was predicted by =2.76 (height at initial evaluation – TH) − 3.68 LH/FSH peaks ratio − 3.49; R2=0.77. Time between puberty onset and first menstruation (years) was predicted by =12.2 – 1.06 age CPP − 0.4 (height at initial evaluation – TH); R2=0.75.

          Conclusions

          A greater difference between height at initial evaluation and TH (SDS) is associated with a greater AH in treated and untreated girls, as are smaller differences between height at initial evaluation and predicted AH in treated and lower LH/FSH peaks ratios in untreated girls.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: not found
          • Article: not found

          Standards for children's height at ages 2-9 years allowing for heights of parents.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Body Mass Index variations: centiles from birth to 87 years.

            This report provides Body Mass Index (weight/height2) values for the French population from birth to the age of 87 years. BMI curves increase during the first year, decrease until the age of 6, increase again up to 65 years and decrease thereafter. These variations reflect the total changes of fat body mass during life. The 50th centile values of Wt/Ht2 at the ages of 20, 40, 60, 80 years are 21.5, 24.6, 25.4, 24.4 kg/m2 for men and 20.6, 22.6, 24.1, 23.4 kg/m2 for women. The values for the 3rd, 50th and 97th centiles in the middle years are approximately 18, 24 and 32 kg/m2. Graphs for these and four other percentiles are plotted against age, and two other graphs summarising the variation and skewness of the Wt/Ht2 distribution are provided to calculate exact percentiles and Z-scores for individuals.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity.

              The objective of the study was to determine whether height gain after discontinuation of gonadotropin-suppressive (GnRHa) therapy differs in girls with sexual precocity diagnosed at various ages and assess its influence on final height (FHt) outcome. We compared data on post-GnRHa treatment course and FHt of 115 girls [22 diagnosed before chronological age of 6 yr; 38 between ages 6 and 8 yr; and 55 early fast puberty (EFP) between ages 8 and 9 yr] treated with GnRHa from Tanner stage 2-3 to chronological age 11-12 yr and bone age 12-12.5 yr. Despite comparable bone age at cessation of treatment, similar time to resumption of puberty (0.6 +/- 0.7, 0.5 +/- 0.7, and 0.5 +/- 0.7 yr), and age at menarche (12.6 +/- 0.5, 12.6 +/- 0.6, and 12.7 +/- 0.9 yr), height gain from cessation of therapy to FHt was greater and time to epiphyseal fusion was longer in the younger central precocious puberty (CPP) than in the older CPP (P < 0.05) and EFP (P < 0.001) groups. The percentage of residual growth predicted at discontinuation of treatment was achieved only by the younger CPP (6.6 +/- 1.6% vs. 6.7 +/- 1.6%), whereas in older CPP and EFP, it was significantly lower (6.2 +/- 1.6% vs. 4.6 +/- 2.7% and 6.3 +/- 1.5% vs. 3.6 +/- 1.5%, respectively). FHt of these two groups was compromised, compared with FHt predicted at discontinuation of treatment (P < 0.01 and P < 0.001, respectively). Girls with sexual precocity diagnosed after the age of 6 yr exhibit earlier epiphyseal fusion with diminished posttreatment height gain and compromised FHt. Because recovery of gonadal axis was similar in all girls, differences were probably due to pretreatment intrinsic changes in the growth plate. Prediction of residual growth at discontinuation of treatment is unreliable in these girls.
                Bookmark

                Author and article information

                Journal
                Med Sci Monit
                Med. Sci. Monit
                Medical Science Monitor
                Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
                International Scientific Literature, Inc.
                1234-1010
                1643-3750
                2011
                01 June 2011
                : 17
                : 6
                : PH41-PH48
                Affiliations
                [1 ]Université Paris Descartes and AP-HP, Hôpital Bicêtre, Unité d’Endocrinologie Pédiatrique, Paris, France
                [2 ]Grenoble-INP/UJF-Grenoble 1/CNRS, G-SCOP UMR5272 Grenoble, France
                [3 ]Center of Diabetes and Endocrinology of Bahia (CEDEBA), Brazil
                [4 ]AP-HP, Hôpital Necker-Enfants Malades, Service d’explorations fonctionnelles, Paris, France
                Author notes
                Raja Brauner, 10 rue Amyot, 75005 Paris, France, e-mail: raja.brauner@ 123456wanadoo.fr
                [*]

                Made equal contributions to the manuscript

                [A]

                Study Design

                [B]

                Data Collection

                [C]

                Statistical Analysis

                [D]

                Data Interpretation

                [E]

                Manuscript Preparation

                [F]

                Literature Search

                [G]

                Funds Collection

                Article
                881794
                10.12659/MSM.881794
                3539549
                21629198
                9698ee49-ea9f-4ce6-a8cd-504f3951d42c
                © Med Sci Monit, 2011

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

                History
                : 22 July 2010
                : 03 November 2010
                Categories
                Public Health

                final height,gonadotropin releasing hormone analogues,idiopathic precocious puberty,mathematical model,puberty,precocious puberty,precocious puberty treatment

                Comments

                Comment on this article